IMUNON Data Monitoring Committee backs continued Phase 2 IMNN-001
IMUNON says its Independent Data Monitoring Committee recommends continuing the Phase 2 MRD study without modification after reviewing safety data to date. It reports no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events observed so far.